emperor-reduced-chmp-positive-opinion

CHMP issues positive opinion for Jardiance ® (empagliflozin) for the treatment of adults with heart failure with reduced ejection fractionThe positive opinion is based on the EMPEROR-Reduced trial, which showed a significant 25 percent reduction in the combined relative risk of cardiovascular death or hospitalization for heart failure  The results were observed in adults with heart failure with reduced ejection fraction (HFrEF), with or without diabetesJardiance is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news